Odanacatib for the treatment of postmenopausal osteoporosis | 2 Minute Medicine
2 Minute Medicine ,
1. The cathepsin K inhibitor odanacatib reduced the risk of fracture but was associated with significantly increased risk of…
Hua Medicine's Pivotal Phase III Monotherapy Trial of Dorzagliatin, a Dual-Acting Glucokinase ...
Medical Health News,
Phase III Monotherapy Trial (HMM0301) of Dorzagliatin Achieves Primary Efficacy Endpoint with 24-Week Topline Results First…
Hua Medicine’s Pivotal Phase III Monotherapy Trial of Dorzagliatin, a Dual-Acting Glucokinase Modulator, Achieves Primary Efficacy Endpoint in Patients with Type 2 Diabetes
Jotup,
The trial achieved its primary efficacy endpoint by demonstrating a statistically significant reduction in HbA1c levels over…
Hua Medicine's Pivotal Phase III Monotherapy Trial of Dorzagliatin, a Dual-Acting Glucokinase Modulator, Achieves Primary Efficacy Endpoint in Patients with Type 2 Diabetes
TMCnet.com,
Phase III Monotherapy Trial (HMM0301) of Dorzagliatin Achieves Primary Efficacy Endpoint with 24-Week Topline Results First…